1. Aeromonas allosaccharophila Strain AE59-TE2 Is Highly Antagonistic towards Multidrug-Resistant Human Pathogens, What Does Its Genome Tell Us?
- Author
-
Sheila da Silva, Fernanda Alves de Freitas Guedes, João Ricardo Vidal Amaral, José Roberto de Assis Ribeiro, Yuri Pinheiro Alves de Souza, Ângela Correa de Freitas-Almeida, Fabiano Lopes Thompson, Rommel Thiago Jucá Ramos, Andrew Steven Whiteley, Andrew Macrae, and Selma Soares de Oliveira
- Subjects
Aeromonas allosaccharophila ,antimicrobial activity ,bacteriocins ,antimicrobial resistance ,genomics ,Science - Abstract
Multidrug-resistant bacteria are of critical importance and a problem for human health and food preservation; the discovery of new antimicrobial substances to control their proliferation is part of the solution. This work reports on 57 antagonistic Aeromonas strains, of which 38 strains were antagonistic towards problematic human pathogens. The genome of the most antagonistic strain was sequenced and identified as Aeromonas allosaccharophila. Its genome was fully annotated and mined for genes that might explain that activity. Strain AE59-TE was antagonistic toward clinically relevant gram-negative and gram-positive multidrug-resistant bacteria, including Klebsiella pneumoniae KPC, Escherichia coli ESBL, Salmonella typhimurium, and Staphylococcus aureus MRSA. Strain AE59-TE2 was identified by multilocus sequence analysis. Genome mining identified four genes homologous to the bacteriocin, zoocin A from Streptococcus equi and a gene 98% similar to cvpA linked to colicin V production. A. allosaccharophila strain AE59-TE2 produced antimicrobial activity against a broad range of bacteria, including important gram-negative bacteria, not typically targeted by bacteriocins. Herewere described novel zoocin genes that are promising for industrial applications in the food and health sectors. Interesting and important antagonistic activity is described combined with the first detailed genomic analysis of the species Aeromonas allosaccharophila.
- Published
- 2022
- Full Text
- View/download PDF